U.S. SEC files suit over possible insider trading on Bioverativ

(Reuters) – The U.S. Securities and Exchange Commission filed an insider trading lawsuit on Friday against “unknown traders” who it said engaged in “highly suspicious trading” just ahead of the announcement that hemophilia specialist Bioverativ Inc had agreed to be acquired by France’s Sanofi in an $11.6 billion deal.


Source: Reuters Health

Roche hemophilia drug lowers costs despite high price: ICER

(Reuters) – A costly new Roche Holding AG drug to treat the bleeding disorder hemophilia A could significantly reduce healthcare expenses for certain patients, a draft report from an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.


Source: Reuters Health